New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Scienture Holdings, Inc.

Contributing Author

Recent Articles by Scienture Holdings, Inc.

Feb-03	SCIENTURE Provides Commercial Update on ARBLI, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium SCNX GlobeNewswire
Jan-14	SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment SCNX GlobeNewswire
Dec-22	SCIENTURE Provides Update on the Commercial Launch of REZENOPY, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA SCNX -8.61% GlobeNewswire
Dec-10	SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium SCNX GlobeNewswire
Dec-02	SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9-10, 2025 SCNX GlobeNewswire
Nov-13	SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update SCNX -5.47% GlobeNewswire
Nov-04	SCIENTURE Announces Addition of Arbli (Losartan Potassium) to Formularies of Major National Health Plans SCNX +15.35% GlobeNewswire
Oct-23	SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli (Losartan Potassium) SCNX +354.94% GlobeNewswire
Oct-16	SCIENTURE'S Arbli Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers SCNX -17.63% GlobeNewswire
Oct-08	SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet SCNX GlobeNewswire
Oct-01	SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli (losartan potassium) to more than 2500 Healthcare Institutions SCNX GlobeNewswire
Sep-16	SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli(losartan potassium) in the $256M U.S. Losartan Market SCNX GlobeNewswire
Aug-14	Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock SCNX -45.50% GlobeNewswire
Aug-13	SCIENTURE announces the shipment of launch quantities of Arbli (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones. SCNX +6.22% GlobeNewswire
Jul-24	Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding SCNX -5.58% GlobeNewswire
Jul-16	Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements SCNX +19.88% GlobeNewswire
Jun-17	Scienture Holdings Announces Cancelation of ELOC SCNX -8.57% GlobeNewswire
May-22	SCIENTURE Announces Executive Leadership Transition SCNX GlobeNewswire
May-19	SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. SCNX +6.51% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.